Oklahoma scientists find interferon-beta may help MS patients on B cell therapy fight infections like flu and Covid-19, new ...

Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplan ...

Updated clinical data in heavily pre-treated, CAR-T naïve patients with B-NHL shows prolonged duration of response, with ...

Explore Fate Therapeutics' pipeline, financials, and market position to assess if its 75% drop reflects true value or ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely focused on CAR-Ts and bispecifics, the German drugmaker has paid Cue ...

The results indicate a prolonged duration of response, significant B-cell depletion, and a well-tolerated safety profile when AlloNK is combined with rituximab. Additionally, the company will ...

TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional ...

Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses. BRIUMVI is indicated in the U.S. for the treatment of adults with RMS ...

Boehringer Ingelheim and Cue Biopharma have announced a partnership worth $357m to develop and commercialise Cue’s pre-clinical B cell depletion therapy for autoimmune diseases. The multi-year ...

One of the best ways to maximize absorption is through proper gut health. Before trying vitamin supplements, it's important ...

The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and ...